| 王 鑫,马宏恩,吕晓燕,赵 伟,贺少辉.托拉塞米联合川芎嗪注射液治疗慢性心力衰竭的疗效及对患者血清MCP-1、BNP、NGAL水平的影响[J].,2019,19(17):3326-3329 |
| 托拉塞米联合川芎嗪注射液治疗慢性心力衰竭的疗效及对患者血清MCP-1、BNP、NGAL水平的影响 |
| Efficacy of Torasemide Combined with Ligustrazine Injection in the treatment of Chronic Heart Failure and Its Effect on the Serum MCP-1, BNP and NGAL Levels |
| 投稿时间：2019-01-21 修订日期：2019-02-17 |
| DOI：10.13241/j.cnki.pmb.2019.17.026 |
| 中文关键词: 托拉塞米 川芎嗪注射液 慢性心力衰竭 单核细胞趋化蛋白因子-1 脑钠肽 中性粒细胞明胶酶相关脂质运载蛋白 |
| 英文关键词: Torasemide Ligustrazine injection Chronic heart failure Monocyte chemoattractant protein factor-1 Brain natriuretic peptide Neutrophil gelatinase-related lipid carrier protein |
| 基金项目:陕西省科学技术研究发展计划支持项目(2011K12-60) |
|
| 摘要点击次数: 548 |
| 全文下载次数: 406 |
| 中文摘要: |
| 摘要 目的：探讨托拉塞米联合川芎嗪注射液治疗慢性心力衰竭的临床疗效及对患者血清单核细胞趋化蛋白因子-1(MCP-1)、脑钠肽(BNP)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)水平的影响。方法：选择2015年3月~2017年3月于我院住院的慢性心力衰竭患者100例，按随机数字表法将其分成治疗组(n=50)与对照组(n=50)。两组患者均给予相同的常规治疗，对照组在此基础上联合托拉塞米治疗，治疗组在对照组基础上加用川芎嗪注射液治疗。在完成2周治疗后，对两组进行疗效评价，比较两组治疗前后心功能、6 min步行距离(6MWT)及生活质量水平、血清MCP-1、BNP、NGAL水平的变化。结果：治疗组经2周治疗后总有效率为86.00%(43/50)，与对照组[64.00%(32/50)]相比显著上升(P<0.05)。治疗组治疗2周后左室射血分数(LVEF)值较治疗前显著升高(P<0.05)，而左室舒张/收缩末期容积(LVEDV/LVESV)均显著降低(P<0.05)；与治疗前对比，对照组治疗后LVEF值亦显著增加(P<0.05)，LVESV值显著下降(P<0.05)；且治疗组治疗后上述心功能指标改善效果均显著优于对照组同期(P<0.05)。与治疗前相比，两组治疗2周后6MWT值均明显增加(P<0.05)，明尼苏达心力衰竭生活质量量表(LHFQ)评分及血清MCP-1、BNP、NGAL水平均明显降低(P<0.05)；且治疗组治疗后以上指标改善效果较对照组同期更显著(P<0.05)。结论：托拉塞米联合川芎嗪注射液治疗慢性心力衰竭的临床疗效明显优于单用川芎嗪注射液治疗，其可有效改善患者心功能，提高生活质量，可能与其显著降低患者血清MCP-1、BNP、NGAL水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of torasemide combined with ligustrazine injection in the treatment of chronic heart failure and its effect on the serum monocyte chemoattractant protein factor-1 (MCP-1), brain natriuretic peptide (BNP) and neutrophil gelatinase - associated lipid transport protein (NGAL) levels. Methods: 100 cases with chronic heart failure in our hospital from March 2015 to March 2017 were selected and randomly divided into the treatment group (n=50) and the control group (n=50). Both groups were given the same routine treatment, torasemide was additionally given to the control group and the treatment group was given torasemide combined with ligustrazine injection. After 2 weeks' treatment, the clinical effect, changes of cardiac function, 6 min walking distance (6MWT), quality of life, serum MCP-1, BNP and NGAL levels before and after treatment were compared between two groups. Results: At 2 weeks after treatment, the overall effective rate was 86.00% (43/50) in the treatment groups, which was significantly higher than that of the control group[64.00% (32/50)](P<0.05). The left ventricular ejection fraction (LVEF) in the treatment groups was significantly higher than that before treatment (P<0.05), and the left ventricular diastolic/systolic volume (LVEDV/LVESV) were significantly decreased(P<0.05). Compared with those before treatment, the LVEF of control group was significantly increased after treatment(P<0.05), wheras the LVESV was significantly decreased(P<0.05). The improvement of cardiac function index after treatment were significantly better than those in control group at the same period(P<0.05). Compared with those before treatment, the 6MWT of both groups at 2 week after treatment were significantly increased(P<0.05), the Minnesota heart failure life quality scale (LHFQ) score, serum MCP-1, BNP and NGAL levels were significantly decreased(P<0.05), and the above index of treatment group were significantly better than those of the control group at the same period(P<0.05). Conclusion: Tolasemide combined with Ligustrazine Injection is more effective than ligustrazine injection alone in treating the chronic heart failure. It can effectively improve the heart function and quality of life, which may be related to the significant reduction of serum levels of MCP-1, BNP and NGAL. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
